All News

Found 605 articles

• Eli Lilly Cuts Ties With University of California, San Diego (UCSD) on $100 Million Alzheimer’s Program

  8/7/2015

• Watch Out Gilead, Investors Feel Vertex May Be Biogen's Good Fit

  8/4/2015

• Biogen Chairman Reassures Investors With $3 Million Stock Buy

  7/29/2015

• Nine Boston Biotechs That Are Actually Profitable

  7/23/2015

• Biogen and Eli Lilly’s Alzheimer’s Drugs Hint At Promise, But Fail To Dazzle

  7/23/2015

• Clinical Trials Results And New Data Analyses In Amyloid-related Therapies From The Alzheimer's Association International Conference 2015

  7/22/2015

• Biogen Presents New Data From Phase IB Study Of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) At Alzheimer’s Association International Conference 2015

  7/22/2015

• New Treatments On The Horizon For Alzheimer’s Disease – Headlines From Alzheimer’s Association International Conference 2015

  7/22/2015

• Investors Excited Over Eli Lilly and Biogen's Upcoming Alzheimer’s Drug Data

  7/21/2015

• Why All Eyes Will Be on Biogen's Alzheimer's Data Next Week

  7/20/2015

• Executive Shuffle and Alzheimer’s Drug Report Creates a Rocky Road for Biogen Stock

  7/14/2015

• AGTC Catapults Premarket on $1 Billion+ Eye Disease Pact With Biogen

  7/6/2015

• Evotec AG, Roche's Alzheimer's Hopeful Fails Another Trial

  7/2/2015

• Axovant Takes Center Stage With Biggest Biotech IPO Ever, Baby-Faced CEO

  6/15/2015

• Buoyed by Biogen, Roche to Take Another Stab at Anti-Amyloid Alzheimer’s Drugs

  6/10/2015

• Cognoptix Release: "2015 World Medical Innovation Forum" Cites "Early Diagnosis And Treatment Of Alzheimer’s Disease" As The Top Field Where Breakthroughs Will Be Made

  5/11/2015

• Advancing Biogen’s Alzheimer’s Treatment Could Cost $2.5 Billion Before Knowing if the Drug Works

  4/28/2015

• In Fight Against Alzheimer's, $100 Million Genentech Trial in Colombia May Be Ground Zero

  4/28/2015

• Biogen Reports First Quarter 2015 Revenues Of $2.6 Billion

  4/24/2015

• Roche Still Bullish on Alzheimer’s Research After Biogen’s Successful Clinical Trial

  4/22/2015